CTR20260647 68Ga-HX01 Soft Tissue Sarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20260647 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 27 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20260647 is a hot trial to watch
Soft Tissue Sarcoma is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20260647 is notable because it evaluates 68Ga-HX01 in a Phase 2 design sponsored by Hexin (Suzhou) Pharmaceutical Technology Co Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20260647 |
| Official title | 评价68Ga-HX01注射液用于不同类型软组织肉瘤PET/CT显像的肿瘤摄取特点、生物分布及安全性的前瞻性、单臂、多中心Ⅱ期临床试验 |
| Phase / status | Phase 2 / 进行中 （招募中） |
| Intervention | 68Ga-HX01 |
| Sponsor | Hexin (Suzhou) Pharmaceutical Technology Co Ltd. |
| Geography | China |
| Enrollment | 1 |
| Primary endpoint | |
| Endpoint time frame | 1年 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 2 study of 68Ga-HX01 in Soft Tissue Sarcoma.
Allocation is 非随机化, masking is 开放, and the intervention model is 单臂试验. Planned enrollment of 1 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (1年) — ？ 评估68Ga-HX01注射液PET/CT显像在软组织肉瘤中的摄取情况以及不同摄取水平下的占比（主要采用基于SUVmax值的半定量分析方法）；
- Primary endpoint (1年) — ？ 观察68Ga-HX01注射液在不同类型软组织肉瘤患者中的生物分布（PET/CT显像），包括各器官及肿瘤标准摄取值（SUV）、给药活度百分比（%ID）和每克组织给药活度百分比（%ID/g）。
- Primary endpoint (1年) — ？ 以临床诊断标准为参考标准，评估68Ga-HX01注射液PET/CT显像用于软组织肉瘤原发灶诊断的灵敏度。
- Primary endpoint (1年) — ？ 软组织肉瘤患者接受单次静脉给予68Ga-HX01注射液后治疗期间不良事件（TEAE）、严重不良事件（SAE）的发生率、严重程度以及相关性（根据美国国家癌症研究所常见不良事件评价标准；
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: 68Ga-HX01 is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Hexin (Suzhou) Pharmaceutical Technology Co Ltd. is resolved to a normalized organization record in Beijing Shi, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20260647 provides a focused lens on Soft Tissue Sarcoma development. Its value will be determined by whether 68Ga-HX01 can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
